Abstract: Provided are a novel agent for inhibiting metastasis of human cancer cells, and a novel agent for determining whether target cells are cancer cells or not in a human. A human cancer cell metastasis inhibitor including human dicalcin or a partial peptide thereof, and a human cancer cell determination agent including human dicalcin or a partial peptide thereof.

Abstract: The present invention is related to the use of HMGB1 antagonists in the treatment and/or prevention and/or inhibition of acute lung injury in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists, in particular K883, in an effective amount to treat and/or prevent and/or inhibit this condition.

Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

Abstract: The present disclosure relates to a BIN1 protein or a BIN1 nucleic acid sequence producing or encoding the same, for a use in the treatment of X-linked centronuclear myopathy. The present invention provides compositions and methods for treatment of X-linked centronuclear myopathy. The present invention relates to a method of delivering the BIN1 polypeptide to subjects with X-linked centronuclear myopathy.

Abstract: Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.

Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).

Abstract: Methods and compositions are disclosed relating to the localization of nucleic acids to arrays such as silane-free arrays, and of sequencing the nucleic acids localized thereby.

Abstract: The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)n-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3)n, or (HM-3)n-Linker-Fc(IgG)-Linker-(HM-3)n. The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

Abstract: The disclosure discloses a method of using PRD, PRD-S, TAD, ZF7 peptide or a mixture thereof to inhibit a cellular response to inflammatory stimuli or treat cytokine-storm-mediated diseases. An amino acid sequence of the PRD peptide is SEQ ID NO: 1, an amino acid sequence of the PRD-S peptide is SEQ ID NO: 2, an amino acid sequence of the TAD peptide is SEQ ID NO: 3, and an amino acid sequence of the ZF7 peptide is SEQ ID NO: 4.

Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

Abstract: A composition includes co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy that are chosen among the co-polyamino acids according to formula XXXb: wherein, D represents, independently, either a group —CH2— (aspartic acid) or a group —CH2—CH2— (glutamic acid), X represents a cationic entity chosen from the group comprising alkali cations, Rb and R?b, identical or different, are either a hydrophobic radical -Hy, or a radical chosen from the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R?b is a hydrophobic radical -Hy, n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5?n+m?250.

Abstract: Provided in the present invention are highly stable D-configuration polypeptides DVAP and SVAP having a high binding activity to the GRP78 protein, and also provided are an L-configuration polypeptide LVAP and a DVAP-or SVAP-modified model drug and a macromolecule carrier material, and the use thereof in the construction of a tumour image and a drug-delivery system for targeted treatment.

Abstract: The present disclosure describes analog conotoxin peptides of the ?-conotoxin peptide RgIA. These analog conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain and inflammation including inflammatory pain, cancer related pain, and neuropathic pain. The RgIA analogs described in the present invention include a variety of sequence modifications and chemical modifications that are introduced to improve the drug-like characteristics of RgIA analogs and thereby increase their therapeutic value.

Abstract: Described are compositions and methods for cartilage replacement. Also described are collagen scaffolds comprising the composition described herein.

Abstract: Disclosed are a pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance. The pharmaceutical composition includes a therapeutically effective amount of a short peptide and morphine as active ingredients, and a pharmaceutically-acceptable carrier. The short peptide is a peptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or a pharmaceutically-acceptable salt thereof. In the method, the short peptide and morphine are administered to a subject simultaneously; or the short peptide is injected to the subject followed by administration of the morphine; or a pharmaceutical composition including the short peptide and morphine is administered to the subject.

Abstract: The invention relates to a new method of determining the presence, absence, number or position(s) of one or more post-translational modifications in a peptide, polypeptide or protein. The invention uses transmembrane pores.

Abstract: The present invention provides peptides and peptide-conjugates that bind to ?v?6 integrin. The peptide-conjugates can be used for a variety of imaging and therapeutic applications. Methods of use and peptide optimization are also provided herein.

Abstract: A cell penetrating conjugate comprising a recombinant ? helical protein linked to a functional molecule wherein the ? helical protein length is in the range of from 5 nm to 25 nm, suitably, from 10 nm to 15 nm and width is in the range of from 1 nm to 5 nm, suitably, from 1 nm to 3 nm. Processes for preparing said conjugates and uses thereof are also disclosed.

Abstract: Provided herein are hemoglobin-based therapeutic agents useful for treating cancer, pharmaceutical composition including the same, and methods of use and preparation thereof.

Abstract: This disclosure provides peptides that bind to LAG3 and can be used to block its interaction with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides, with their demonstrated activity and short half-life, can be used to activate cellular immunity while significantly reducing the potential for adverse events that is often associated with the antibody-based checkpoint inhibitors. The peptides can be used as stand-alone therapeutics or can be used as immune modulators in combination with other therapies.